Aquabounty Technologies Inc (NASDAQ:AQB) had a decrease of 16.16% in short interest. AQB’s SI was 192,500 shares in April as released by FINRA. Its down 16.16% from 229,600 shares previously. With 129,300 avg volume, 2 days are for Aquabounty Technologies Inc (NASDAQ:AQB)’s short sellers to cover AQB’s short positions. The SI to Aquabounty Technologies Inc’s float is 22.05%. The stock decreased 5.00% or $0.17 during the last trading session, reaching $3.23. About 33,051 shares traded. AquaBounty Technologies, Inc. (NASDAQ:AQB) has declined 73.06% since April 16, 2017 and is downtrending. It has underperformed by 84.61% the S&P500.
Analysts expect Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to report $-0.66 EPS on May, 10.They anticipate $0.34 EPS change or 106.25% from last quarter’s $-0.32 EPS. After having $-0.64 EPS previously, Reata Pharmaceuticals, Inc.’s analysts see 3.13% EPS growth. The stock increased 4.19% or $0.89 during the last trading session, reaching $22.15. About 135,337 shares traded. Reata Pharmaceuticals, Inc. (NASDAQ:RETA) has declined 19.56% since April 16, 2017 and is downtrending. It has underperformed by 31.11% the S&P500.
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company has market cap of $579.34 million. The Company’s lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of Friedreich's ataxia, mitochondrial myopathies, and metastatic melanoma. It currently has negative earnings. The firm was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.
AquaBounty Technologies, Inc., a biotechnology company, develops and markets products to enhance productivity in aquaculture. The company has market cap of $40.94 million. The Company’s lead product is the AquAdvantage Salmon, a genetically modified animal for human consumption. It currently has negative earnings. The firm was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004.